Castrate-Resistant Prostate Cancer

Oncology
4
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Teva
TevaIsrael - Petach Tikva
1 program
1
custirsen sodiumPhase 31 trial
Active Trials
NCT01083615Terminated14Est. Mar 2013
Achieve Life Sciences
1 program
1
custirsen sodiumPhase 3
Novartis
NovartisBASEL, Switzerland
1 program
1
BEZ235Phase 1/21 trial
Active Trials
NCT01717898Terminated6Est. Aug 2016
Ionis Pharmaceuticals
1 program
1
ISIS EIF4E RxPhase 1/21 trial
Active Trials
NCT01234025Completed113Est. Dec 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Tevacustirsen sodium
NovartisBEZ235
Ionis PharmaceuticalsISIS EIF4E Rx

Clinical Trials (3)

Total enrollment: 133 patients across 3 trials

NCT01083615Tevacustirsen sodium

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Start: Mar 2010Est. completion: Mar 201314 patients
Phase 3Terminated

A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer

Start: Jan 2013Est. completion: Aug 20166 patients
Phase 1/2Terminated

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

Start: Nov 2010Est. completion: Dec 2013113 patients
Phase 1/2Completed

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
4 companies competing in this space